Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.7 EUR
127.00 M EUR
684.60 M EUR
About BIOTEST AG
Sector
CEO
Peter Janssen
Headquarters
Dreieich
Website
Founded
1946
ISIN
DE0005227235
FIGI
BBG000BF9LL4
Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BIO3 is 27.2 EUR — it has increased by 0.73% in the past 24 hours. Watch BIOTEST AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange BIOTEST AG stocks are traded under the ticker BIO3.
BIO3 stock hasn't changed in a week, the month change is a 0.73% rise, over the last year BIOTEST AG has showed a −12.82% decrease.
BIO3 reached its all-time high on Oct 18, 2021 with the price of 44.5 EUR, and its all-time low was 0.8 EUR and was reached on Mar 25, 2003. View more price dynamics on BIO3 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BIO3 stock is 1.10% volatile and has beta coefficient of 0.11. Track BIOTEST AG stock price on the chart and check out the list of the most volatile stocks — is BIOTEST AG there?
Today BIOTEST AG has the market capitalization of 1.09 B, it has increased by 1.17% over the last week.
Yes, you can track BIOTEST AG financials in yearly and quarterly reports right on TradingView.
BIOTEST AG is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
BIO3 net income for the last quarter is −9.30 M EUR, while the quarter before that showed 9.70 M EUR of net income which accounts for −195.88% change. Track more BIOTEST AG financial stats to get the full picture.
Yes, BIO3 dividends are paid annually. The last dividend per share was 0.08 EUR. As of today, Dividend Yield (TTM)% is 0.29%. Tracking BIOTEST AG dividends might help you take more informed decisions.
As of Nov 21, 2024, the company has 2.43 K employees. See our rating of the largest employees — is BIOTEST AG on this list?
Like other stocks, BIO3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOTEST AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOTEST AG technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOTEST AG stock shows the sell signal. See more of BIOTEST AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.